A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma ; volume:6 ; number:1 ; day:06 ; month:12 ; year:2006 ; pages:1-5 ; date:12.2006
BMC cancer ; 6, Heft 1 (06.12.2006), 1-5, 12.2006
- Creator
-
Bekaii-Saab, Tanios
- Contributor
-
Williams, Nita
Plass, Christoph
Calero, Miguel Villalona
Eng, Charis
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-6-278
- URN
-
urn:nbn:de:1111-2016030341927
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bekaii-Saab, Tanios
- Williams, Nita
- Plass, Christoph
- Calero, Miguel Villalona
- Eng, Charis
- SpringerLink (Online service)
Other Objects (12)
Oncogene induced senescence via the tyrosine kinase receptor ERBB2 : characterisation by mRNA expression analysis and raman micro-spectroscopy
Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients
X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
Dual inhibition of epidermal growth factor receptor and erb-b2 receptor tyrosine kinase 3 : implications for therapeutic targeting in head and neck squamous cell carcinoma
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
Oncogene induced senescence via the tyrosine kinase receptor ERBB2 : characterisation by mRNA expression analysis and raman micro-spectroscopy
Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients
X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
Dual inhibition of epidermal growth factor receptor and erb-b2 receptor tyrosine kinase 3 : implications for therapeutic targeting in head and neck squamous cell carcinoma
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
Oncogene induced senescence via the tyrosine kinase receptor ERBB2 : characterisation by mRNA expression analysis and raman micro-spectroscopy
Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients
X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
Dual inhibition of epidermal growth factor receptor and erb-b2 receptor tyrosine kinase 3 : implications for therapeutic targeting in head and neck squamous cell carcinoma
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status